Ventricular AP
phase 0: rapid depolarisation by Na influx from -90 to +30
phase 1: initial K efflux
phase 2: prolonged inflow Ca, enables AP to be prolonged and prevents tetany
phase 3: further K efflux
phase 4: resting potential
Nodal AP
Phase 4: sloping voltage gradually reduces until -60 where hits threshold for depolarisation, Ca enters through L type cells
Phase 3:
Sodium channel blockers
Class 1
flecainide, lidocaine, disopyramide, phenytoin
prolongs QRS
block fast Na channels
slow depolarisation
widen QRS
pro-arrhythmic risk
Beta blockers
block beta adrenoreceptors
B1 receptors in heart
Gs protein-coupled - chemical on outside (norad or adre) attaches to ligand which produces secondary messenger e.g. increases cAMP and protein kinase A
leads to increase L type Ca channel opening -> increase Ca in cardiac cells -> increased HR -> increased contractility
B1 blockade -> reduced cAMP -> less Ca entry -> AV nodal slowing -> reduced contractility
Amiodarone
potassium channel blockers
delays process of K coming back into cells
prolongs repolarisation and slows HR
prolong QT
doesn’t work in torsades du point
blocks most atrial and ventricular arrhythmias
Calcium channel blockers
diltiazem and verapamil
block L type Ca channels
slows AV conduction
negatively inotropic
Adenosine
acts on A1 receptor
increases K+ out of cell
reduces Ca 2+ influx
transient AV blockade
acts on Gi protein-couple receptor -> inhibits cAMP -> reduces Ca influx
Digoxin
inhibits Na/K ATPase
intracelluar Na rises
affects Na/Ca exchanger leading to less Na movement in and less Ca leaves cell -> increased intracellular Ca -> more Ca release from SR during systole -> positive inotropic effect
potassium competes with digoxin for binding at Na/K ATPase
low K means less competition -> more dig binding -> greater pump inhibition -> more Ca accumulation -> more arrhythmias
RAAS
decrease in renal perfusion (low pressure in afferent arteriole) -> renin released from macula densa
renin acts on angiotensinogen, cleaves to angiotensin I
ACE concerts to angiotensin II in lungs
angiotenisn II:
- increase sympathetic activity
- tubular NaCl reabsorption and K+ excretion, H2O retention
- stimulates aldosterone sercretion
- arteriolar vasoconstriction
- stimulates ADH secretion from post lobe pit, increased water reabsorption
ACE inhibitors
prevent bradykinin being broken down, inflammatory mediator
adverse effects:
- cough
- angiooedema
- hyperkalaemia
- renal impairment
Angiotensin Receptor Blockers
block AT1 receptors
don’t get adverse effects of bradykinin
AT1 receptors are where most angiotensin II acts
Aldosterone antagonists
block aldosterone receptor
potassium sparing
mild diuretic
spironolactone or eplerenone
Diuretics overview
loop: act on Na+-K+ co transporter
thiazide: Na+-Cl- co transporter
potassium sparing: ENaC and aldosterone antagonists
Loop diuretics
acts on NKCC co transporter on loop of henle
particularly thick ascending limb
blocks Na/K/2Cl on apical membrane of cell so reduces movement of Na/K/Cl into cell from lumen of nephron -> lose Na -> increases tubular fluid -> diuresis
thiazide
act on distal convoluted tubule
block NaCl symporter - loose NaCl (Na exchanged for K further down tubule so higher levels of Na lead to more K loss)
bendoflumethiazide
hypokalaemia
hyperuricaemia and hyperglycaemia
interaction with lithium - reduced circulating Na leads to increased reabsorption in proximal tubule - lithium also reabsorbed there -> less renal clearance of lithium
Potassium sparing diuretics
block ENaC in distal tubule
reduces Na reabsorption in distal tubule
amiloride, triamterene
Calcium Channel Blockers
block L type calcium channels
reduces Ca entry into cells
vascular smooth muscle relaxation -> vasodilation
reduced cardiac contractility
slowed AV node conduction
dihydropyridines - don’t act on heart, main action on SM e.g. amlodipine and nifedipine, predominantly vascular effects
adverse effects - peripheral oedema, flushing, headache, reflex tachycardia
non-dihydropyridines - verapamil and diltiazem
slows AV node conduction by blocking Ca uptake, used for arrhythmias
adverse effects: bradycardia, heart block (if used with beta blockers), reduced cardiac contractility, constipation
Severe Hypertension
malignant HTN and pre eclampsia
reduce BP gradually
labetalol - combined a1 and b blocker, reduces peripheral vascular resistance without large reflex tachycardia
nicardipine - CCB causing arterial vasodilation
GTN - veno and coronary vasodilation
hydralazine - arterial vasodilator
Inotropes and vasopressors
act on adrenoreceptors
G protein coupled - increase intracellular Ca
adrenaline:
- beta - increase HR, increase contractility, dilate coronary arteries, bronchodilation
- alpha - vasoconstriction of skin and splanchnic vessels
noradrenaline - acts on alpha receptors, a1 smooth muscle, a2 on pre synaptic receptor (causes inhibition of synapse)
dobutamine - B1 agonist
Coagulation cascade
intrinsic pathway
Factor Xa/antithrombins
catalyses prothrombin to thrombin
factor Xa blockers - unfractionated heparin, LMWH, fondaparinus
work through changing shape of antithrombin III which acts on factor Xa
LMWH - removed various weights of heparin, more predictable than unfractionated heparin (lots bound by plasma, requires APTT monitoring)
bleeding in LMWH or unfractionated heparin can be reversed by protamine
fondaparinux
synthetic, pentasaccharide related to heparin
binds antithrombin -> selective inhibition on factor Xa
lower risk of HIT
Warfarin
inhibits vit K recycling
reduced factors II, VII, IX, X
takes days
DOACs
dabigatran factor IIa inhibitor, reversed by idarucizumab (monoclonal Ab)
factor Xa inhibitors e.g. apix or rivaroxaban
reversal agent andexanet alfa
Reversal in major bleeding:
- prothrombin complex concentrate
antiplatelets
aspirin:
- irreversible COX-1 inhibitor
- cannot form thromboxane
- platelet has no nucleus so cannot make more, blocked for life span (5-7 days)
clopidogrel, prasugrel and ticagrelor
- P2Y12 blockade
- block ADP mediated platelet activation
clopidogrel - prodrug (needs activation), irreversible P2Y12 receptor inhibitor, hepatic activation
prasugrel - prodrug, more potent and faster than clopi
ticagrelor - direct reversible P2Y12 inhibitor, rapid onset, stronger platelet inhibition